explore -WSS

explore

author：leisure time 2025-10-03 00:47:30 - browse：5

Adam's take main illustration — Molly Ferguson/STAT

Shares of Apellis Pharmaceuticals are rebounding, driven by a growing belief among some investors that the serious safety issue that has derailed Syfovre, the company’s eye disease treatment, is receding.

Declaring the crisis over is premature, but that could change with more uneventful weeks. Apellis has been a takeout target before, and may be again, at an acquisition price nearly twice its current market value.

Apellis shares rose 32% last week, with most of the gains coming Friday on heavy trading volume. The reason: There have been no new cases of retinal occlusive vasculitis, or ROV, reported in people receiving injections of Syfovre.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Doctors are clamoring for more clarity on Paxlovid prescribing

WSS

Readout Newsletter: Amylyx, Aurinia, and IQVIA

St. Louis police protesters begin picking up checks in $4.9 million settlement

Pennsylvania man bitten on the head by bear during attack in his garage

Latigo launches with $135 million for Vertex

Severe weather updates: 1 million customers without power in 11 states as storms pummel East Coast

Trump used to be more articulate. What could explain the change?

hotspot

explore

hotspot

In Memoriam: Notable people who died in 2023

STAT Boddities: What happens to the brain when we get scared?

Tori Bowie and the unacceptable rates of Black maternal death

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

Virginia high school admissions case could be legal follow

Pennsylvania man bitten on the head by bear during attack in his garage

Trump demands the U.S. pay no more for drugs than other countries … again

AMAs digital advisors table RPM coding reform proposal, again

In Memoriam: Notable people who died in 2023

Severe weather updates: 1 million customers without power in 11 states as storms pummel East Coast

explore

Resistance to opioid

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

Juul documents reveal insider tactics on political lobbying

St. Louis police protesters begin picking up checks in $4.9 million settlement

Severe weather updates: 1 million customers without power in 11 states as storms pummel East Coast

McConnell is warmly embraced by Kentucky Republicans amid questions about his health

hotspot

leisure time

leisure time

explore